Results 121 to 130 of about 24,893 (251)

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Pediatric nephrology (Berlin, West), 2020
Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disease associated with poor outcomes if untreated. Ravulizumab, a long-acting C5 inhibitor developed through minimal, targeted modifications to eculizumab was recently approved for
Kazuki Tanaka, B. Adams, Á. M. Aris, N. Fujita, M. Ogawa, S. Ortiz, M. Vallée, L. Greenbaum   +7 more
semanticscholar   +1 more source

Hemolytic uremic syndrome and IgA nephropathy in a child: Coincidence or not?

The Turkish Journal of Pediatrics, 2018
A previously healthy 18-month old boy, presenting with diarrhea, anemia, thrombocytopenia and acute renal failure was admitted to our hospital. Hemolytic uremic syndrome (HUS) was diagnosed with his clinical and laboratory findings.
Serra Sürmeli-Döven, Ali Delibaş, İclal Gürses, Uğur Raşit Kayacan, Banu Coşkun-Yılmaz, Kaan Esen, Emine Korkmaz, Fatih Özaltın   +7 more
doaj   +1 more source

Meningococcal Serogroup Y Meningitis Reveals Inborn Factor B Deficiency

European Journal of Immunology, Volume 56, Issue 2, February 2026.
We report a novel case of complete complement Factor B deficiency revealed by invasive meningococcal disease. Using combined functional and genetic analyses, we demonstrate that loss of Factor B abolishes alternative pathway activity despite detectable protein levels. These findings provide a mechanistic framework relevant to complement diagnostics and
Camille Bougeard, Eléonore Eskander, Paula Vieira Martins, Joan Bitan, Julia Roquigny, Christèle Kyheng, Tamazoust Guiddir, Véronique Frémeaux‐Bacchi, Cécile Gonnin, Carine ElSissy   +9 more
wiley   +1 more source

Clinical case of thrombotic microangiopathy in obstetric practice

Сеченовский вестник, 2017
Trombotic microangiopathy is heterogeneous group of the diseases united by a community of a histological and clinical implications at difference of pathogenetic mechanisms, presents clinical-morphological syndrome characterizing a lesion of vessels of a ...
M. N. Mochalova, T. E. Belokrinitskaya, T. V. Haven, E. M. Shifman, K. G. Shapovalov, S. V. Kostromitin   +5 more
doaj  

A Case of Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Annals of Internal Medicine: Clinical Cases
Atypical hemolytic uremic syndrome (aHUS) is a rare non-Shiga toxin thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway.
Kwasi Opare-Addo, Sammudeen Ibrahim, Basilio Addo, Jorge Chancay Rodriguez   +3 more
doaj   +1 more source

ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case)

Вестник анестезиологии и реаниматологии, 2018
The article describes the follow-up over the development of atypical hemolytic-uremic syndrome in the female patient suffering menometrorrhagia which manifested with concurrent metrorrhagia and was accompanied with acute renal failure.
A. V. Pyregov, T. A. Fedorova, A. Yu. Korolev, K. I. Grischuk   +3 more
doaj   +1 more source

The Complement System in ANCA‐Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
Complement activation, particularly via the alternative pathway, drives inflammation and organ damage in ANCA‐associated vasculitis. This review highlights mechanistic insights, tissue and biomarker evidence, and clinical implications of targeting the C5a–C5aR1 axis.
Kehinde Sunmboye, Pauline Millan
wiley   +1 more source

Current treatment of atypical hemolytic uremic syndrome

Intractable & Rare Diseases Research, 2014
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.).
Bernard S, Kaplan, Rebecca L, Ruebner, Joann M, Spinale, Lawrence, Copelovitch   +3 more
openaire   +3 more sources

Modulators of Diacylglycerol Kinase Activity: A Review of Advances and Challenges

Medicinal Research Reviews, Volume 46, Issue 1, Page 149-175, January 2026.
ABSTRACT Catalyzing the conversion of diacylglycerol (DAG) in phosphatidic acid (PA), diacylglycerol kinases (DGKs) play a pivotal role in all the physiological processes modulated by these two bioactive lipids, such as lipid metabolism and immune regulation.
Luisa Racca, Gianluca Baldanzi, Alberto Massarotti   +2 more
wiley   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source